早期应用低分子肝素对慢性阻塞性肺疾病急性加重期的影响  

Early application of low molecular heparin on AECOPD patients

作　　者：沈威[1] 翁婷[1] 高蔚[1] 

机构地区：[1]南京鼓楼医院集团宿迁市人民医院,江苏宿迁223800

出　　处：《临床肺科杂志》2016年第12期2274-2276,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨慢性阻塞性肺疾病急性加重期(AECOPD)早期治疗中应用低分子肝素的临床价值。方法选取2014-2015年收治的AECOPD患者80例,随机平均分为两组,对照组患者给予常规治疗,研究组患者增加低分子肝素治疗。结果治疗后研究组患者临床治疗显效率与有效率均明显高于对照组(P<0.05)。治疗后研究组SPAP、PaO_2、PaCO_2、红细胞压积、血浆粘度、全血高切粘度、全血低切粘度均明显优于对照组(P<0.05)。结论 AECOPD患者早期应用低分子肝素能够有效提高临床疗效,改善血气分析以及血液流变学指标,缓解高凝血状态以及低血氧状况。Objective To study the application value of low molecular heparin on AECOPD patients. Meth- oils 80 patients with AECOPD from 2014 to 2015 were randomly divided into two groups. The control group was giv- en routine therapy, and the study group was additionally treated with low molecular heparin. Results The clinical efficiency and effectiveness were significantly higher in the study group than in the control group after treatment （ P 〈 0. 05 ）, and the levels of SPAP, PaO2, PaCO2, red blood cells deposited, plasma viscosity, whole blood high shear viscosity, and whole blood low shear viscosity were all significantly better in the study group than in the control group （P 〈 0. 05 ）. Conclusion The early application of low molecular heparin can effectively improve the clinical cura- tive effect, blood gas analysis and hemorheology indexes, alleviate high coagulation state and low oxygen condition in treatment of AECOPD patients.

关 键 词：早期 低分子肝素 慢性阻塞性肺疾病 急性加重期 AECOPD 

分 类 号：R563.9[医药卫生—呼吸系统]